Santachiara et al7 reported on 87 late CP patients treated with imatinib who presented a reduction of Ig levels; these patients were treated with imatinib after IFN for CML or were affected by GIST. This evidence concerns the gene IFNA1 and gastrointestinal stromal tumor.